Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity

R. Y. van der Velde, C. E. Wyers, E. Teesselink, P. P. M. M. Geusens, J. P. W. van den Bergh, F. de Vries, C. Cooper*, N. C. Harvey, T. P. van Staa

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

42 Citations (Web of Science)
28 Downloads (Pure)

Abstract

Introduction: Given the expected increase in the number of patients with osteoporosis and fragility fractures it is important to have concise information on trends in prescription rates of anti-osteoporosis drugs (AOD). M

ethods: We undertook a retrospective observational study using the UK Clinical Practice Research Datalink (CPRD) in the UK between 1990 and 2012 in subjects 50 years or older, stratified by age, sex, geographic region and ethnicity. Yearly prescription incidence rates of any AOD and of each specific AOD were calculated as the number of patients first prescribed these AODs per 10,000 person-years (py).

Results: In women, yearly rates of first prescription of any AOD increased from 1990 to 2006 (from 23 to 169.7 per 10,000 py), followed by a plateau and a 12% decrease in the last three years. In men, a less steep increase from 1990 to 2007 (from 1.4 to 45.3 per 10,000 py) was followed by a plateau from 2008 onwards. Yearly rates of first prescription of any AOD increased up to the age of 85-89 years (248.9 per 10,000 py in women. and 1193 in men). There were marked differences between ethnic groups and regions. Bisphosphonates were the most frequently prescribed AODs: etidronate till 2000, and then subsequently alendronate.

Conclusion: We have demonstrated marked secular changes in rates of anti-osteoporosis drug prescription over the last two decades. The plateau (and decrease amongst women) in rates in recent years, set against an ever ageing population, is worrying, suggesting that the well-documented care gap in osteoporosis treatment persists. The differences in prescription rates by geographic location and ethnicity raise intriguing questions in relation to underlying fracture rates, provision of care and health behaviour.

Summary: We studied the prescription incidence of anti-osteoporosis drugs (AOD) from 1990 to 2012 in the UK CPRD. Overall AOD prescription incidence showed a strong increase from 1990 to 2006, followed by a plateau in both sexes and a decrease amongst women in the last three years. (C) 2016 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)50-55
Number of pages6
JournalBone
Volume94
DOIs
Publication statusPublished - Jan 2017

Keywords

  • Osteoporosis
  • Epidemiology
  • Anti-osteoporosis drugs
  • AOD
  • Fracture
  • Secular trends
  • RANDOMIZED CONTROLLED-TRIAL
  • PRACTICE RESEARCH DATABASE
  • POSTMENOPAUSAL WOMEN
  • HIP FRACTURE
  • PRIMARY-CARE
  • UK
  • POPULATION
  • RISK
  • BISPHOSPHONATES
  • DISPARITIES

Cite this